On the 24th, GENCURIX, a company specializing in cancer molecular diagnosis, noted that its annual revenue nearly doubled last year, surpassing 5 billion won.
According to GENCURIX's announcement, the separate revenue for last year was 5.13377 billion won, marking a 97.4% increase compared to 2023. During the same period, the operating loss decreased from 11.15855 billion won in 2023 to 8.42395 billion won, a reduction of approximately 24.5%.
GENCURIX explained that its revenue increased due to a growing market share of its main products and that the operating loss decreased due to cost efficiency. It is said that the number of prescriptions for GENCURIX's main product, "GeneSwell BCT," increased by approximately 130% compared to 2023.
GENCURIX explained that it has also escaped the requirements for being designated as a management item through a capital increase. As of the end of last year, GENCURIX's total equity was 15 billion won, and the ratio of the loss before tax (4 billion won) to total equity was 27%. If this ratio exceeds 50%, it could be designated as a management item.
A representative from GENCURIX said, "This year, we expect to generate significant sales overseas as we are engaged in product development and supply contracts with global corporations such as Hitachi High-Technologies, Roche Diagnostics, and Bio-Rad."